Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProctoFiz MD
- Development stage
- Unknown
- Lead developer
- ESPA Biomedical
- Administration
- Rectal, Topical
01
Overview
ProctoFiz MD is a plant-based topical cream developed by ESPA Biomedical for the management and treatment of chronic anal fissures. Registered as a medical device with the Israeli Ministry of Health, the formulation contains a synergistic blend of natural ingredients, including hemp seed oil, calendula, sweet almond, myrtle, arnica, and seaweed extract. It acts as a local anesthetic, antiseptic, anti-inflammatory, and skin-regenerating agent to alleviate pain, reduce bleeding, and promote wound healing. In Israel, it is marketed in partnership with CTS.
- Brand names
- ProctoFizProctoFiz MD
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on ProctoFiz MD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProctoFiz MD.